未经证实:停止抗病毒治疗慢性乙型肝炎(CHB)患者导致较高的乙型肝炎表面抗原(HBsAg)损失;然而,可能发生临床复发(CR)。SCALE-B评分用于预测治疗外CR;然而,超过48周随访的SCALE-B验证很少.我们研究了SCALE-B和乙型肝炎病毒核糖核酸(HBVRNA)是否可以预测2年随访后CHB患者的预后。
UNASSIGNED:共有92名泰国CHB患者停止抗病毒治疗进行了随访;基线特征,定量乙型肝炎表面抗原(qHBsAg),乙型肝炎核心相关抗原(HBcrAg),和HBVRNA在停药时收集,并计算SCALE-B评分。患者每12周随访一次,共48周,然后,间隔是在初级医生。关于病毒学复发(VR)的随访数据,CR,并获得HBsAg消失。
UNASSIGNED:中位随访时间为142周;VR的累积发生率,CR,HBsAg消失分别为65.2,33.7和7.6%,分别。48周后,VR和CR趋于稳定,但HBsAg消失从2.2增加到7.6%。根据SCALE-B地层,VR,CR,和HBsAg消失有显著差异。最高层(≥320)与较高的VR相关,CR,与最低层相比,HBsAg损失较小,调整后的危险比为5.0(95%CI:1.8-14.4),10.44(95%CIs:1.4-79.1),和0.04(95%CIs:0.004-0.43),分别。
未经评估:在停止治疗后2.5年的中位随访时间,泰国患者的HBsAg消失被发现随着时间的推移而增加。SCALE-B是预测CR的有价值的工具,VR,和HBsAg消失;HBVRNA与长期结局没有显着相关。
未经批准:[www.ClinicalTrials.gov],标识符[TCTR20180316007]。
UNASSIGNED: Discontinuation of antiviral therapy in chronic hepatitis B (CHB) patients leads to a higher hepatitis B surface antigen (HBsAg) loss; yet, clinical relapse (CR) may occur. SCALE-B score was developed to predict off-treatment CR; however, validation of SCALE-B beyond a 48-week follow-up is rare. We studied whether SCALE-B and hepatitis B virus ribonucleic acid (HBV RNA) could predict outcomes in CHB patients after a 2-year follow-up.
UNASSIGNED: A total of 92 Thai CHB patients who stopped antiviral treatment were followed up; baseline characteristics, quantitative hepatitis B surface antigen (qHBsAg), hepatitis B core-related antigen (HBcrAg), and HBV RNA were collected at the time of discontinuation, and SCALE-B scores were calculated. Patients were followed up every 12 weeks for 48 weeks, and then, the intervals were upon primary doctors. Follow-up data regarding virological relapse (VR), CR, and HBsAg loss were obtained.
UNASSIGNED: The median follow-up duration was 142 weeks; the cumulative incidences of VR, CR, and HBsAg loss were 65.2, 33.7, and 7.6%, respectively. After 48 weeks, VR and CR plateaued, but HBsAg loss increased from 2.2 to 7.6%. According to the SCALE-B strata, VR, CR, and HBsAg loss were significantly different. The highest stratum (≥ 320) was associated with higher VR, CR, and lesser HBsAg loss when compared to the lowest stratum, with adjusted hazard ratios of 5.0 (95% CIs: 1.8-14.4), 10.44 (95% CIs: 1.4-79.1), and 0.04 (95% CIs: 0.004-0.43), respectively.
UNASSIGNED: At a median follow-up of 2.5 years after discontinuing therapy, HBsAg loss in Thai patients was found to increase over time. SCALE-B is a valuable tool for predicting CR, VR, and HBsAg loss; HBV RNA is not significantly associated with long-term outcomes.
UNASSIGNED: [www.ClinicalTrials.gov], identifier [TCTR20180316007].